Terms: = Head and neck cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
56 results:
1. FUT8-mediated aberrant N-glycosylation of SEMA7A promotes head and neck squamous cell carcinoma progression.
Liu Z; Meng X; Zhang Y; Sun J; Tang X; Zhang Z; Liu L; He Y
Int J Oral Sci; 2024 Mar; 16(1):26. PubMed ID: 38548747
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic role of pd-l1 expression in head and neck squamous cell carcinoma: An institutional experience from India.
Kala PS; Thapliyal N; Pant B; Sharma N; Pandey HS
Pathol Res Pract; 2024 Feb; 254():155133. PubMed ID: 38306860
[TBL] [Abstract] [Full Text] [Related]
3. pd-l1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer.
Kawasaki K; Noma K; Kato T; Ohara T; Tanabe S; Takeda Y; Matsumoto H; Nishimura S; Kunitomo T; Akai M; Kobayashi T; Nishiwaki N; Kashima H; Maeda N; Kikuchi S; Tazawa H; Shirakawa Y; Fujiwara T
Cancer Immunol Immunother; 2023 Nov; 72(11):3787-3802. PubMed ID: 37668710
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Significance of the Microenvironment in Human Papillomavirus Oropharyngeal Carcinoma: A Systematic Review.
Baudouin R; Hans S; Lisan Q; Morin B; Adimi Y; Martin J; Lechien JR; Tartour E; Badoual C
Laryngoscope; 2024 Apr; 134(4):1507-1516. PubMed ID: 37642393
[TBL] [Abstract] [Full Text] [Related]
5. Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Ji D; Jiang S; Zhang Q; Wang YK; Zhang J; Shen W; Li W; Liu R; Wang J; Mavis C; Gu JJ; Hu X
Clin Transl Sci; 2023 Aug; 16(8):1396-1407. PubMed ID: 37317057
[TBL] [Abstract] [Full Text] [Related]
6. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Saba NF; Steuer CE; Ekpenyong A; McCook-Veal A; Magliocca K; Patel M; Schmitt NC; Stokes W; Bates JE; Rudra S; Remick J; McDonald M; Abousaud M; Tan AC; Fadlullah MZH; Chaudhary R; Muzaffar J; Kirtane K; Liu Y; Chen GZ; Shin DM; Teng Y; Chung CH
Nat Med; 2023 Apr; 29(4):880-887. PubMed ID: 37012550
[TBL] [Abstract] [Full Text] [Related]
7. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract] [Full Text] [Related]
8. Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for head and neck cancer.
Wagner SM; Magnes T; Melchardt T; Kiem D; Weiss L; Neureiter D; Wagner C; Aretin MB; Nemec S; Gamerith G; Pall G; Greil R; Fuereder T
Anticancer Res; 2023 Mar; 43(3):1273-1282. PubMed ID: 36854497
[TBL] [Abstract] [Full Text] [Related]
9. The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.
Mühlenbruch L; Abou-Kors T; Dubbelaar ML; Bichmann L; Kohlbacher O; Bens M; Thomas J; Ezić J; Kraus JM; Kestler HA; von Witzleben A; Mytilineos J; Fürst D; Engelhardt D; Doescher J; Greve J; Schuler PJ; Theodoraki MN; Brunner C; Hoffmann TK; Rammensee HG; Walz JS; Laban S
Br J Cancer; 2023 May; 128(9):1777-1787. PubMed ID: 36823366
[TBL] [Abstract] [Full Text] [Related]
10. Targeting tumor-intrinsic pd-l1 suppresses the progression and aggressiveness of head and neck cancer by inhibiting GSK3β-dependent Snail degradation.
Ahn CH; Oh KY; Jin B; Lee WW; Kim J; Kim HJ; Park DG; Swarup N; Chawla K; Ryu MH; Kim UK; Choi SJ; Yoon HJ; Hong SD; Shin JA; Cho SD
Cell Oncol (Dordr); 2023 Apr; 46(2):267-282. PubMed ID: 36441378
[TBL] [Abstract] [Full Text] [Related]
11. Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer.
Bell RB; Gough M; Crittenden M; Young K
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 36106641
[TBL] [Abstract] [Full Text] [Related]
12. pd-l1 expression in 117 sinonasal mucosal melanomas and its association with clinical outcome.
Wang L; Liu H
Ann Diagn Pathol; 2022 Oct; 60():151976. PubMed ID: 35660809
[TBL] [Abstract] [Full Text] [Related]
13. Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.
Ma X; Guo Z; Wei X; Zhao G; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao L; Yuan Z; Wang P; Pang Q; Yan C; Zhang W
Front Immunol; 2021; 12():786429. PubMed ID: 35046943
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic significance of T-cell-inflamed gene expression profile and pd-l1 expression in patients with esophageal cancer.
Steiniche T; Rha SY; Chung HC; Georgsen JB; Ladekarl M; Nordsmark M; Jespersen ML; Kim HS; Kim H; Fein C; Tang LH; Wu T; Marton MJ; Peter S; Kelsen DP; Ku G
Cancer Med; 2021 Dec; 10(23):8365-8376. PubMed ID: 34693652
[TBL] [Abstract] [Full Text] [Related]
15. SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
Tanaka I; Dayde D; Tai MC; Mori H; Solis LM; Tripathi SC; Fahrmann JF; Unver N; Parhy G; Jain R; Parra ER; Murakami Y; Aguilar-Bonavides C; Mino B; Celiktas M; Dhillon D; Casabar JP; Nakatochi M; Stingo F; Baladandayuthapani V; Wang H; Katayama H; Dennison JB; Lorenzi PL; Do KA; Fujimoto J; Behrens C; Ostrin EJ; Rodriguez-Canales J; Hase T; Fukui T; Kajino T; Kato S; Yatabe Y; Hosoda W; Kawaguchi K; Yokoi K; Chen-Yoshikawa TF; Hasegawa Y; Gazdar AF; Wistuba II; Hanash S; Taguchi A
J Natl Cancer Inst; 2022 Feb; 114(2):290-301. PubMed ID: 34524427
[TBL] [Abstract] [Full Text] [Related]
16. Oncogene-specific differences in tumor mutational burden, pd-l1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
17. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic head and neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract] [Full Text] [Related]
18. Molecular Features of cancer-associated Fibroblast Subtypes and their Implication on cancer Pathogenesis, Prognosis, and Immunotherapy Resistance.
Galbo PM; Zang X; Zheng D
Clin Cancer Res; 2021 May; 27(9):2636-2647. PubMed ID: 33622705
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic Impact of PD-1 on Tumor-Infiltrating Lymphocytes in 433 Resected Esophageal cancers.
Nomoto D; Baba Y; Okadome K; Yagi T; Kalikawe R; Kiyozumi Y; Harada K; Eto K; Hiyoshi Y; Nagai Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Watanabe M; Baba H
Ann Thorac Surg; 2022 Jan; 113(1):286-294. PubMed ID: 33482156
[TBL] [Abstract] [Full Text] [Related]
20. Significance of druggable targets (pd-l1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract] [Full Text] [Related]
[Next]
